IL-35、IL-39、IL-27在肿瘤微环境中的调节作用

摘要/Abstract

摘要：

白细胞介素(IL)家族能直接或间接地刺激肿瘤细胞增殖、存活和扩散,并进一步塑造肿瘤微环境,从而在一定程度上影响肿瘤的生长与转化。研究发现IL-12家族的新成员IL-35、IL-39、IL-27在多种肿瘤中发挥相关的特异性免疫功能,可能是肿瘤研究的重要靶向分子。

刘赛赛, 袁东亚. IL-35、IL-39、IL-27在肿瘤微环境中的调节作用[J]. 国际肿瘤学杂志, 2021, 48(4): 212-215.

Liu Saisai, Yuan Dongya. Regulation of IL-35, IL-39 and IL-27 in tumor microenvironment[J]. Journal of International Oncology, 2021, 48(4): 212-215.

参考文献32

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34. DOI: 10.3322/caac.21551. doi:10.3322/caac.v69.1
[2]	Teymouri M, Pirro M, Fallarino F, et al. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases[J]. Int J Cancer, 2018, 143(9):2105-2115. DOI: 10.1002/ijc.31382. doi:10.1002/ijc.v143.9
[3]	Huang C, Li N, Li Z, et al. Tumour-derived interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression[J]. Nat Commun, 2017, 8:14035. DOI: 10.1038/ncomms14035. doi:10.1038/ncomms14035
[4]	Wang K, Gong H, Chai R, et al. RETRACTED: aberrant frequency of IL-35 producing B cells in colorectal cancer patients[J]. Cytokine, 2018, 102:206-210. DOI: 10.1016/j.cyto.2017.10.011. doi:S1043-4666(17)30316-2pmid:29054723
[5]	Yang M, Zhang Z, Chen J, et al. Soluble fibrinogen-like protein 2 promotes the growth of hepatocellular carcinoma via attenuating dendritic cell-mediated cytotoxic T cell activity[J]. J Exp Clin Cancer Res, 2019, 38(1):351. DOI: 10.1186/s13046-019-1326-5. doi:10.1186/s13046-019-1326-5
[6]	Hao S, Chen X, Wang F, et al. Breast cancer cell-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells[J]. Carcinogenesis, 2018, 39(12):1488-1496. DOI: 10.1093/carcin/bgy136. doi:10.1093/carcin/bgy136
[7]	Heim L, Kachler K, Siegmund R, et al. Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer[J]. Br J Cancer, 2019, 120(9):903-912. DOI: 10.1038/s41416-019-0444-3. doi:10.1038/s41416-019-0444-3
[8]	Larousserie F, Kebe D, Huynh T, et al. Evidence for IL-35 expression in diffuse large B-cell lymphoma and impact on the patient's prognosis[J]. Front Oncol, 2019, 9:563. DOI: 10.3389/fonc.2019.00563. doi:10.3389/fonc.2019.00563pmid:31316915
[9]	Zhu J, Yang X, Wang Y, et al. Interleukin-35 is associated with the tumorigenesis and progression of prostate cancer[J]. Oncol Lett, 2019, 17(6):5094-5102. DOI: 10.3892/ol.2019.10208.
[10]	Takahashi R, Macchini M, Sunagawa M, et al. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression[J]. Gut, 2021: 70(2):330-341. DOI: 10.1136/gutjnl-2019-319912.
[11]	Zhang X, Zhang Z, Ju M, et al. Pretreatment with interleukin 35-engineered mesenchymal stem cells protected against lipopolysaccharide-induced acute lung injury via pulmonary inflammation suppression[J]. Inflammopharmacology, 2020, 28(5):1269-1281. DOI: 10.1007/s10787-020-00696-5. doi:10.1007/s10787-020-00696-5
[12]	Li X, Fang P, Sun Y, et al. Anti-inflammatory cytokines IL-35 and IL-10 block atherogenic lysophosphatidylcholine-induced, mitochondrial ROS-mediated innate immune activation, but spare innate immune memory signature in endothelial cells[J]. Redox Biol, 2020, 28:101373. DOI: 10.1016/j.redox.2019.101373. doi:10.1016/j.redox.2019.101373
[13]	Carvalho MI, Pires I, Prada J, et al. Assessing the interleukin 35 immunoexpression in malignant canine mammary tumors: association with clinicopathological parameters and prognosis[J]. Anticancer Res, 2019, 39(4):2077-2083. DOI: 10.21873/anticanres.13319. doi:10.21873/anticanres.13319
[14]	Turnis ME, Sawant DV, Szymczak-Workman AL, et al. Interleukin-35 limits anti-tumor immunity[J]. Immunity, 2016, 44(2):316-329. DOI: 10.1016/j.immuni.2016.01.013. doi:10.1016/j.immuni.2016.01.013
[15]	Zou JM, Qin J, Li YC, et al. IL-35 induces N2 phenotype of neutrophils to promote tumor growth[J]. Oncotarget, 2017, 8(20):33501-33514. DOI: 10.18632/oncotarget.16819. doi:10.18632/oncotarget.v8i20
[16]	Lee CC, Lin JC, Hwang WL, et al. Macrophage-secreted interleukin-35 regulates cancer cell plasticity to facilitate metastatic colonization[J]. Nat Commun, 2018, 9(1): 3763. DOI: 10.1038/s41467-018-06268-0. doi:10.1038/s41467-018-06268-0
[17]	Wang X, Liu X, Zhang Y, et al. Interleukin (IL)-39 [IL-23p19/Epstein-Barr virus-induced 3 (Ebi3)] induces differentiation/expansion of neutrophils in lupus-prone mice[J]. Clin Exp Immunol, 2016, 186(2):144-156. DOI: 10.1111/cei.12840. doi:10.1111/cei.12840
[18]	Wang X, Wei Y, Xiao H, et al. A novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like mice[J]. Eur J Immunol, 2016, 46(6):1343-1350. DOI: 10.1002/eji.201546095. doi:10.1002/eji.201546095
[19]	Floss DM, Schönberg M, Franke M, et al. IL-6/IL-12 cytokine receptor shuffling of extra- and intracellular domains reveals canonical STAT activation via synthetic IL-35 and IL-39 signaling[J]. Sci Rep, 2017, 7(1): 15172. DOI: 10.1038/s41598-017-15173-3. doi:10.1038/s41598-017-15173-3
[20]	Manning AA, Zhao L, Zhu Z, et al. IL-39 acts as a friend to pancreatic cancer[J]. Med Oncol, 2019, 36(1): 12. DOI: 10.1007/s12032-018-1236-y.
[21]	Guo Y, Cao W, Zhu Y. Immunoregulatory functions of the IL-12 family of cytokines in antiviral systems[J]. Viruses, 2019, 11(9): 772. DOI: 10.3390/v11090772.
[22]	Figueiredo ML, Figueiredo Neto M, Salameh JW, et al. Ligand-mediated targeting of cytokine interleukin-27 enhances its bioactivity in vivo[J]. Mol Ther Methods Clin Dev, 2020, 17:739-751. DOI: 10.1016/j.omtm.2020.03.022. doi:10.1016/j.omtm.2020.03.022
[23]	Carbotti G, Petretto A, Naschberger E, et al. Cytokine-induced guanylate binding protein 1 (GBP1) release from human ovarian cancer cancer cells[J]. Cancers(Basel), 2020, 12(2): 488. DOI: 10.3390/cancers12020488.
[24]	Le HT, Keslar K, Nguyen QT, et al. Interleukin-27 enforces regulatory T cell functions to prevent graft-versus-host disease[J]. Front Immunol, 2020, 11:181. DOI: 10.3389/fimmu.2020.00181. doi:10.3389/fimmu.2020.00181
[25]	Figueiredo Neto M, Liu S, Salameh JW, et al. Interleukin-27 gene delivery targeting IL-6Rα-expressing cells as a stress response therapy[J]. Int J Mol Sci, 2020, 21(3): 1108. DOI: 10.3390/ijms21031108. doi:10.3390/ijms21031108
[26]	Lavoie S, Chun E, Bae S, et al. Expression of free fatty acid receptor 2 by dendritic cells prevents their expression of interleukin 27 and is required for maintenance of mucosal barrier and immune response against colorectal tumors in mice[J]. Gastroenterology, 2020, 158(5):1359-1372.e9.DOI: 10.1053/j.gastro.2019.12.027. doi:10.1053/j.gastro.2019.12.027
[27]	Hu A, Ding M, Zhu J, et al. Intra-tumoral delivery of IL-27 using adeno-associated virus stimulates anti-tumor immunity and enhances the efficacy of immunotherapy[J]. Front Cell Dev Biol, 2020, 8:210. DOI: 10.3389/fcell.2020.00210. doi:10.3389/fcell.2020.00210
[28]	Hawley JE, Pan S, Figg WD, et al. Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy[J]. Prostate, 2020, 80(4):336-344. DOI: 10.1002/pros.23948. doi:10.1002/pros.v80.4
[29]	Hemati M, Rasouli Nejad Z, Shokri MR, et al. IL-27 impact on NK cells activity: implication for a robust anti-tumor response in chronic lymphocytic leukemia[J]. Int Immunopharmacol, 2020, 82:106350. DOI: 10.1016/j.intimp.2020.106350. doi:10.1016/j.intimp.2020.106350
[30]	Rocha GA, de Melo FF, Cabral MMDA, et al. Interleukin-27 is abrogated in gastric cancer, but highly expressed in other Helicobacter pylori-associated gastroduodenal diseases[J]. Helicobacter, 2020, 25(1): e12667. DOI: 10.1111/hel.12667.
[31]	Manouchehri-Doulabi E, Abbaspour S, Rostami S, et al. Evaluating the mechanism underlying antitumor effect of interleukin 27 on B cells of chronic lymphocytic leukemia patients[J]. J Cell Physiol, 2020, 235(12):9424-9431. DOI: 10.1002/jcp.29747. doi:10.1002/jcp.v235.12
[32]	Zhu J, Liu JQ, Shi M, et al. IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy[J]. JCI Insight, 2018, 3(7):e98745. DOI: 10.1172/jci.insight.98745. doi:10.1172/jci.insight.98745

IL-35、IL-39、IL-27在肿瘤微环境中的调节作用

Regulation of IL-35, IL-39 and IL-27 in tumor microenvironment

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献32

相关文章15

编辑推荐

Metrics

本文评价

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[3]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[4]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	傅旖, 马辰莺, 张露, 周菊英.生境分析在恶性肿瘤影像组学中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 292-297.
[7]	张文馨, 夏泠, 彭晋, 周福祥.甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇.信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[9]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[10]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[11]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[12]	钟楠, 王淡瑜, 周欢欢, 刘宁, 戴纬, 刘黎琼, 郭智.CD30单抗联合PD-1抑制剂治疗复发难治性霍奇金淋巴瘤的疗效与安全性[J]. 国际肿瘤学杂志, 2024, 51(4): 245-248.
[13]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	钱晓涛, 石子宜, 胡格.Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.